Detailed information for compound 109271
Basic information
Technical information
- TDR Targets ID: 109271
- Name: 3-(6-aminopyridin-3-yl)-2-[1-(3-methylbutyl)i midazol-4-yl]propanoic acid
- MW: 302.371 | Formula: C16H22N4O2
-
H donors: 2
H acceptors: 4
LogP: 1.71
Rotable bonds: 7
Rule of 5 violations (Lipinski): 1 - SMILES: CC(CCn1cnc(c1)C(C(=O)O)Cc1ccc(nc1)N)C
- InChi: 1S/C16H22N4O2/c1-11(2)5-6-20-9-14(19-10-20)13(16(21)22)7-12-3-4-15(17)18-8-12/h3-4,8-11,13H,5-7H2,1-2H3,(H2,17,18)(H,21,22)
- InChiKey: FUZLEHIZFGSVSF-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- 3-(6-amino-3-pyridyl)-2-(1-isopentylimidazol-4-yl)propanoic acid
- 3-(6-amino-3-pyridyl)-2-(1-isopentyl-4-imidazolyl)propanoic acid
- 3-(6-azanylpyridin-3-yl)-2-[1-(3-methylbutyl)imidazol-4-yl]propanoic acid
- 3-(6-amino-3-pyridyl)-2-(1-isoamylimidazol-4-yl)propionic acid
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | carboxypeptidase B1 (tissue) | Starlite/ChEMBL | References |
| Homo sapiens | carboxypeptidase B2 (plasma) | Starlite/ChEMBL | References |
| Homo sapiens | carboxypeptidase A1 (pancreatic) | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Echinococcus multilocularis | subfamily M14A unassigned peptidase | carboxypeptidase B1 (tissue) | 417 aa | 421 aa | 30.6 % |
| Echinococcus multilocularis | subfamily M14A unassigned peptidase | carboxypeptidase A1 (pancreatic) | 419 aa | 402 aa | 33.1 % |
| Loa Loa (eye worm) | hypothetical protein | carboxypeptidase B2 (plasma) | 386 aa | 324 aa | 34.9 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Echinococcus multilocularis | subfamily M14A unassigned peptidase | 0.0205 | 0.5 | 0.5 |
| Onchocerca volvulus | Subfamily M14A unassigned peptidase homolog | 0.0205 | 0.5 | 0.5 |
| Onchocerca volvulus | 0.0205 | 0.5 | 0.5 | |
| Schistosoma mansoni | subfamily M14A unassigned peptidase (M14 family) | 0.0205 | 0.5 | 0.5 |
| Onchocerca volvulus | 0.0205 | 0.5 | 0.5 | |
| Onchocerca volvulus | 0.0205 | 0.5 | 0.5 | |
| Onchocerca volvulus | 0.0205 | 0.5 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Bleeding time (functional) | = 2 min | Tested in vivo for bleeding time in african green monkey when administered along with saline | ChEMBL. | 14640538 |
| Bleeding time (functional) | = 2 min | Tested in vivo for bleeding time in african green monkey when administered at a dose of 0.03 mg/kg iv bolus + 0.01 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| Bleeding time (functional) | = 2.2 min | Tested in vivo for bleeding time in african green monkey when administered at a dose of 0.05 mg/kg iv bolus + 0.02 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| Bleeding time (functional) | = 2.3 min | Tested in vivo for bleeding time in african green monkey when administered at a dose of 0.1 mg/kg iv bolus + 0.03 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| Bleeding time (functional) | = 2.9 min | Tested in vivo for bleeding time in african green monkey when administered at a dose of 0.3 mg/kg iv bolus + 0.1 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| Cl (ADMET) | = 6.1 ml min-1 kg-1 | Clearance of the compound was determined in dog | ChEMBL. | 14640538 |
| Cl (ADMET) | = 6.1 ml min-1 kg-1 | Clearance of the compound was determined in rhesus | ChEMBL. | 14640538 |
| Cl (ADMET) | = 32 ml min-1 kg-1 | Clearance of the compound was determined in rat | ChEMBL. | 14640538 |
| CLT50 (functional) | = 0.056 uM | Concentration of compound that gives 50% of the maximum acceleration of lysis was determined by clot lysis assay using human plasma | ChEMBL. | 14640538 |
| CLT50 (functional) | = 0.12 uM | Concentration of compound that gives 50% of the maximum acceleration of lysis was determined by clot lysis assay using human plasma | ChEMBL. | 14640538 |
| CLT50 (functional) | == 0.12 uM | Concentration providing 50% acceleration of clot lysis in pooled human plasma | ChEMBL. | 15080996 |
| Concentration (functional) | = 0 uM | Tested in vivo for steady state plasma concentration in african green monkey when administered along with saline | ChEMBL. | 14640538 |
| Concentration (functional) | = 2.4 uM | Tested in vivo for steady state plasma concentration in african green monkey when administered at a dose of 0.03 mg/kg iv bolus + 0.01 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| Concentration (functional) | = 5.7 uM | Tested in vivo for steady state plasma concentration in african green monkey when administered at a dose of 0.05 mg/kg iv bolus + 0.02 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| Concentration (functional) | = 9.6 uM | Tested in vivo for steady state plasma concentration in african green monkey when administered at a dose of 0.1 mg/kg iv bolus + 0.03 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| Concentration (functional) | = 26.1 uM | Tested in vivo for steady state plasma concentration in african green monkey when administered at a dose of 0.3 mg/kg iv bolus + 0.1 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| F (ADMET) | = 12 % | Bioavailability of the compound was determined in rhesus | ChEMBL. | 14640538 |
| F (ADMET) | = 38 % | Bioavailability in dog | ChEMBL. | 14640538 |
| F (ADMET) | = 47 % | Bioavailability in rat | ChEMBL. | 14640538 |
| IC50 (functional) | = 0.002 uM | In vitro inhibition of thrombin-activatable fibrinolysis was determined by clot lysis assay using human plasma | ChEMBL. | 14640538 |
| IC50 (binding) | = 0.0027 uM | In vitro inhibition of purified Carboxypeptidase B (CPB) by clot lysis assay in human plasma | ChEMBL. | 14640538 |
| IC50 (binding) | = 0.0027 uM | In vitro inhibition of purified Carboxypeptidase B (CPB) by clot lysis assay in human plasma | ChEMBL. | 14640538 |
| IC50 (binding) | = 0.004 uM | In vitro inhibition of purified Carboxypeptidase B (CPB) by clot lysis assay in human plasma | ChEMBL. | 14640538 |
| IC50 (binding) | = 0.004 uM | Inhibition of human carboxypeptidase B (CPB) | ChEMBL. | 15080996 |
| IC50 (binding) | = 0.004 uM | In vitro inhibition of purified Carboxypeptidase B (CPB) by clot lysis assay in human plasma | ChEMBL. | 14640538 |
| IC50 (binding) | = 0.004 uM | Inhibition of human carboxypeptidase B (CPB) | ChEMBL. | 15080996 |
| IC50 (functional) | = 0.005 uM | In vitro inhibition of thrombin-activatable fibrinolysis was determined by clot lysis assay using human plasma | ChEMBL. | 14640538 |
| IC50 (binding) | = 0.005 uM | Inhibitory potency against human TAFIa (thrombin-activatable fibrinolysis inhibitor) | ChEMBL. | 15080996 |
| IC50 (binding) | = 0.005 uM | Inhibitory potency against human TAFIa (thrombin-activatable fibrinolysis inhibitor) | ChEMBL. | 15080996 |
| IC50 (binding) | = 1.4 uM | In vitro inhibition of Carboxypeptidase A (CPA) was determined by clot lysis assay using human plasma | ChEMBL. | 14640538 |
| IC50 (binding) | = 1.4 uM | In vitro inhibition of Carboxypeptidase A (CPA) was determined by clot lysis assay using human plasma | ChEMBL. | 14640538 |
| IC50 (binding) | = 2.2 uM | In vitro inhibition of Carboxypeptidase A (CPA) was determined by clot lysis assay using human plasma | ChEMBL. | 14640538 |
| IC50 (binding) | = 2.2 uM | In vitro inhibition of Carboxypeptidase A (CPA) was determined by clot lysis assay using human plasma | ChEMBL. | 14640538 |
| IC50 (binding) | > 50 uM | In vitro inhibition of purified Carboxypeptidase N (CPN) by clot lysis assay in human plasma | ChEMBL. | 14640538 |
| IC50 (binding) | > 50 uM | In vitro inhibition of purified Carboxypeptidase M (CPM) by clot lysis assay in human plasma | ChEMBL. | 14640538 |
| IC50 (binding) | > 50 uM | In vitro inhibition of purified Carboxypeptidase M (CPM) by clot lysis assay in human plasma | ChEMBL. | 14640538 |
| Selectivity (binding) | = 0.8 | Selectivity for TAFIa versus CPB carboxypeptidase B isoforms | ChEMBL. | 15080996 |
| T1/2 (ADMET) | = 0.6 hr | Half life of the compound was determined in dog | ChEMBL. | 14640538 |
| T1/2 (ADMET) | = 0.8 hr | Half life of the compound was determined in rhesus | ChEMBL. | 14640538 |
| T1/2 (ADMET) | = 1.1 hr | Half life of the compound was determined in rat | ChEMBL. | 14640538 |
| TTO (functional) | = 51 min | Tested in vivo for time-to-occlusion in carotid artery of african green monkey when administered along with saline | ChEMBL. | 14640538 |
| TTO (functional) | = 52 min | Tested in vivo for time-to-occlusion in carotid artery of african green monkey when administered at a dose of 0.1 mg/kg iv bolus + 0.03 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| TTO (functional) | = 61 min | Tested in vivo for time-to-occlusion in carotid artery of african green monkey when administered at a dose of 0.03 mg/kg iv bolus + 0.01 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| TTO (functional) | = 62 min | Tested in vivo for time-to-occlusion in carotid artery of african green monkey when administered at a dose of 0.05 mg/kg iv bolus + 0.02 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| TTO (functional) | = 85 min | Tested in vivo for time-to-occlusion in carotid artery of african green monkey when administered at a dose of 0.3 mg/kg iv bolus + 0.1 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| TTO (functional) | = 96 min | Tested in vivo for time-to-occlusion in jugular vein of african green monkey when administered along with saline | ChEMBL. | 14640538 |
| TTO (functional) | = 128 min | Tested in vivo for time-to-occlusion in jugular vein of african green monkey when administered at a dose of 0.03 mg/kg iv bolus + 0.01 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| TTO (functional) | = 147 min | Tested in vivo for time-to-occlusion in jugular vein of african green monkey when administered at a dose of 0.05 mg/kg iv bolus + 0.02 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| TTO (functional) | = 171 min | Tested in vivo for time-to-occlusion in jugular vein of african green monkey when administered at a dose of 0.1 mg/kg iv bolus + 0.03 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| TTO (functional) | = 216 min | Tested in vivo for time-to-occlusion in jugular vein of african green monkey when administered at a dose of 0.3 mg/kg iv bolus + 0.1 mg/(kg.min) continuous infusion | ChEMBL. | 14640538 |
| Vdss (ADMET) | = 0.26 l kg-1 | Volume of distribution of the compound was determined in rhesus | ChEMBL. | 14640538 |
| Vdss (ADMET) | = 0.28 l kg-1 | Volume of distribution of the compound was determined in dog | ChEMBL. | 14640538 |
| Vdss (ADMET) | = 1.36 l kg-1 | Volume of distribution of the compound was determined in rat | ChEMBL. | 14640538 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL68399
- PubChem: 9926432
Bibliographic References
2 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.